替格瑞洛与氯吡格雷相比在血小板抑制和患者预后（PLATO）试验中的效应大小：从统计学到临床判断 - Suppr | 超能文献

Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial: from statistics to clinical judgment.

作者信息

Capodanno Davide, Calvi Valeria, Tamburino Corrado

出版信息

J Cardiovasc Med (Hagerstown). 2012 Feb;13(2):162-3. doi: 10.2459/JCM.0b013e32834f23bd.

DOI:10.2459/JCM.0b013e32834f23bd

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial: from statistics to clinical judgment.替格瑞洛与氯吡格雷相比在血小板抑制和患者预后（PLATO）试验中的效应大小：从统计学到临床判断

J Cardiovasc Med (Hagerstown). 2012 Feb;13(2):162-3. doi: 10.2459/JCM.0b013e32834f23bd.

2

Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.替格瑞洛与氯吡格雷用于老年急性冠脉综合征患者的疗效比较：前瞻性随机血小板抑制与患者预后（PLATelet inhibition and patient Outcomes，PLATO）试验的一项子研究

Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):680-8. doi: 10.1161/CIRCOUTCOMES.111.964395.

3

Antiplatelet therapy: Ticagrelor in ACS-what does PLATO teach us?抗血小板治疗：替格瑞洛在急性冠脉综合征中的应用——PLATO研究给我们带来了什么启示？

Nat Rev Cardiol. 2009 Dec;6(12):737-8. doi: 10.1038/nrcardio.2009.192.

4

Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.首个可逆性口服P2Y(12)受体拮抗剂替格瑞洛与氯吡格雷在急性冠脉综合征患者中的比较：血小板抑制和患者预后（PLATO）试验的原理、设计及基线特征

Am Heart J. 2009 Apr;157(4):599-605. doi: 10.1016/j.ahj.2009.01.003.

5

Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.PLATO 研究显示，与氯吡格雷相比，替格瑞洛降低了首次和复发的心血管事件。

Circulation. 2013 Feb 12;127(6):673-80. doi: 10.1161/CIRCULATIONAHA.112.124248. Epub 2012 Dec 31.

6

Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.替格瑞洛与氯吡格雷治疗伴外周动脉疾病的急性冠脉综合征患者的心血管事件：来自 PLATO 试验的数据。

Eur J Prev Cardiol. 2015 Jun;22(6):734-42. doi: 10.1177/2047487314533215. Epub 2014 May 15.

7

Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.替格瑞洛与氯吡格雷在肾功能相关的急性冠状动脉综合征中的比较：来自血小板抑制和患者结局（PLATO）试验的结果。

Circulation. 2010 Sep 14;122(11):1056-67. doi: 10.1161/CIRCULATIONAHA.109.933796. Epub 2010 Aug 30.

8

ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy.PLATO 试验中的 ST 段抬高急性冠状动脉综合征：来自心电图子研究的见解。

Circulation. 2012 Jan 24;125(3):514-21. doi: 10.1161/CIRCULATIONAHA.111.047530. Epub 2011 Dec 16.

9

Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.替格瑞洛对比氯吡格雷对急性冠状动脉综合征患者血小板功能的抑制作用：PLATO（血小板抑制和患者结局）研究的血小板亚研究。

J Am Coll Cardiol. 2010 Oct 26;56(18):1456-62. doi: 10.1016/j.jacc.2010.03.100.

10

Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?替格瑞洛--急性冠脉综合征患者的新型血小板聚集抑制剂。能改善其他抑制剂吗？

Med Sci Monit. 2009 Dec;15(12):MS24-30.

引用本文的文献

1

Antiplatelet agents for chronic kidney disease.抗血小板药物在慢性肾脏病中的应用。

Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD008834. doi: 10.1002/14651858.CD008834.pub4.

2

Ticagrelor Use in Indian Patients Undergoing Neuroendovascular Procedures: A Single Center Experience.替格瑞洛在接受神经血管内介入手术的印度患者中的应用：单中心经验

Neurointervention. 2019 Sep;14(2):125-130. doi: 10.5469/neuroint.2019.00087. Epub 2019 Aug 7.